Francesca Aroldi, discusses the early efficacy data with RP2 in advanced solid tumors.
Francesca Aroldi, clinical research fellow, University of Oxford, discusses the early efficacy data with RP2 in advanced solid tumors.
During the 2020 SITC Virtual Congress, initial findings from the dose-exploration portion of a phase 1 trial (NCT04336241) were presented. The results demonstrated encouraging clinical activity with single-agent RP2, a genetically modified herpes simplex-1 oncolytic, says Aroldi.
Furthermore, 2 heavily pretreated patients with immune-insensitive disease had ongoing partial responses at 9 months, says Aroldi. One patient had esophageal cancer and the other had uveal melanoma. Notably, 1 patient with pretreated mucoepidermoid carcinoma had an ongoing complete response, Aroldi says.
Additionally, one patient with microsatellite-stable colorectal adenocarcinoma who was pretreated with chemotherapy and a vaccine appears to be responding to RP2 based on second CT scan findings, Aroldi explains.
The dose-expansion portion of the trial has enrolled 10 patients and will evaluate RP2 in combination with nivolumab (Opdivo).